Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

scientific article

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1049790432
P356DOI10.1038/ONC.2013.497
P8608Fatcat IDrelease_kt2npdofdbaivn42hcfbxciwx4
P932PMC publication ID4876694
P698PubMed publication ID24276248

P2093author name stringC G Drake
P Sharma
W Gerritsen
P2860cites workGlobal cancer statisticsQ22241238
Hallmarks of Cancer: The Next GenerationQ22252312
Abiraterone in metastatic prostate cancer without previous chemotherapyQ24612084
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerQ24633070
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerQ24684241
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyQ26851608
Circulating tumors cells as biomarkers: progress toward biomarker qualificationQ26852579
Sipuleucel-T immunotherapy for castration-resistant prostate cancerQ27860648
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaQ28131634
Cancer despite immunosurveillance: immunoselection and immunosubversionQ28263865
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyQ28275476
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerQ29616123
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerQ29616218
Increased survival with enzalutamide in prostate cancer after chemotherapyQ29617511
Abiraterone and increased survival in metastatic prostate cancerQ29617512
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapyQ29619961
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialQ29620155
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupQ33566395
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancerQ33952036
Development of Ipilimumab: Contribution to a New Paradigm for Cancer ImmunotherapyQ34149569
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer modelsQ34150018
Novel therapies for metastatic castrate-resistant prostate cancerQ34249263
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancerQ34368408
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancerQ34415510
Activation of thymic regeneration in mice and humans following androgen blockadeQ34440551
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerQ34543188
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ34620634
Prostate cancer as a model for tumour immunotherapyQ34856875
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidenceQ35076330
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialQ83427167
Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancerQ114738516
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabQ35289145
Castration-resistant prostate cancer: systemic therapy in 2012Q35865011
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaQ35871798
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failuresQ36181578
Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsQ36185518
The anticancer immune response: indispensable for therapeutic success?Q36677608
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II studyQ36999978
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapyQ37193043
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancementQ37193049
Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablationQ37268005
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibodyQ37351567
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.Q37418671
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effectQ37821337
Contribution of the immune system to the chemotherapeutic response.Q37832967
How to improve the immunogenicity of chemotherapy and radiotherapyQ37836489
Combining immunotherapy and targeted therapies in cancer treatmentQ37995939
Melanoma as a model tumour for immuno-oncologyQ38037486
Immunohistochemistry in the era of personalised medicineQ38045874
Identification of docetaxel resistance genes in castration-resistant prostate cancerQ39452736
Increased expression of class III beta-tubulin in castration-resistant human prostate cancerQ39811005
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacyQ39829746
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockadeQ39894616
Radiotherapy augments the immune response to prostate cancer in a time-dependent mannerQ40080152
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumorQ40412166
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killingQ40543778
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy developmentQ41915850
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerQ42032055
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapyQ42180889
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.Q42927772
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinomaQ44080958
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumorsQ44542342
The role of immunotherapy in prostate cancer: an overview of current approaches in development.Q44947041
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyQ46817220
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.Q50966333
Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.Q53099425
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancerQ56903097
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing miceQ56907375
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancerQ60156266
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancerQ60368025
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapyQ73496463
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejectionQ80284129
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouseQ81999205
P433issue43
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
immunotherapyQ1427096
P304page(s)5053-64
P577publication date2014-10-23
P1433published inOncogeneQ1568657
P1476titleMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
P478volume33

Reverse relations

cites work (P2860)
Q96353886A Multimodal Theranostic Nanoformulation that Dramatically Enhances Docetaxel Efficacy Against Castration Resistant Prostate Cancer
Q98947294ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Q36782633Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop
Q37709535Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles
Q41573500Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
Q37390666Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
Q64113560Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase
Q38364647Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer
Q47307286Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.
Q36433756Diagnosis of prostatic carcinoma on multiparametric magnetic resonance imaging using shearlet transform
Q48176349Immunotherapy for Prostate Cancer: Where We Are Headed
Q42022308MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling
Q39333529Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.
Q37718328Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways
Q39340541Personalized peptide vaccines and their relation to other therapies in urological cancer
Q47757361Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells
Q41858027SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
Q28251240Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
Q33821011Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

Search more.